Regenerative Therapies Market, By Tissue Type (Allograft, Xenograft, Alloplast), By Application type (Soft Tissue Repair, Cardiovascular, Dental, Orthoped, CNS disease treatment,Others), By End user (Hospitals, Ambulatory Surgical Centers, Educational Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 93.56 Billion in 2023 and is expected to exhibit a CAGR of 15.7% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The regenerative therapies market is experiencing remarkable growth and innovation, offering new hope for patients with debilitating conditions. Stem cell therapies, gene editing technologies, and tissue engineering are driving advancements in regenerative medicine. These approaches hold the potential to restore and regenerate damaged tissues and organs, revolutionizing healthcare. The market is attracting significant investments and collaborations from pharmaceutical companies, startups, and academic institutions, reflecting its commercial potential. However, challenges such as ensuring safety, navigating regulations, and addressing affordability and accessibility need to be overcome. Nonetheless, regenerative medicine has the potential to transform patient care and provide transformative solutions to complex medical conditions.
In November 29, 2022, AstraZeneca acquires Neogene Therapeutics for up to US$ 320 million, expanding its access to next-generation T-cell receptor therapies for solid tumor targeting. This strategic move strengthens AstraZeneca's commitment to revolutionize cancer treatment and bring innovative cell therapies to patients. TCR-Ts offer a unique approach by recognizing intracellular targets, including cancer-specific mutations. Neogene's expertise in TCR-T discovery and manufacturing complements AstraZeneca's oncology cell therapy capabilities. The transaction is expected to close in Q1 2023, subject to regulatory approvals.
September 20, 2022, MiMedx Group, Inc. (Nasdaq: MDXG) has launched AXIOFILL, an ECM Particulate product derived from human placental tissue, targeting the Surgical Recovery market. AXIOFILL offers a cost-effective and versatile solution for large and complex wounds, providing surgeons with the option to use it as a dry particulate or a paste. The proprietary processing technique preserves key structural proteins, making AXIOFILL biocompatible and conducive to tissue regeneration. This addition to MiMedx's product portfolio demonstrates their commitment to customer-driven innovation and addressing unmet clinical needs in the Surgical Recovery market.
Regenerative Therapies Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.
The COVID-19 pandemic had both positive and negative impacts on the global regenerative therapies market. On the positive side, it led to increased research and development, accelerated clinical trials, and redirected efforts towards vaccine development. However, the pandemic also disrupted ongoing clinical trials, created funding challenges, caused supply chain disruptions, and presented regulatory hurdles. In the long term, the impact on the market will depend on effectively overcoming these challenges and capitalizing on the lessons learned during this time.
Global Regenerative Therapies Market Market Market: Key Developments
Regenerative medicine is diversifying its applications beyond tissue repair and wound care, extending into fields such as cardiology, neurology, oncology, and more. Companies are actively conducting clinical trials to establish their dominance by introducing innovative products and therapies, disrupting traditional treatment methods
April 2022 ,The FDA has approved Yescarta as the first CAR T-cell therapy for initial treatment of relapsed or refractory large B-cell lymphoma. It demonstrated a significant improvement in event-free survival and a higher likelihood of patients being alive at two years without disease progression compared to standard of care. Yescarta also received a Category 1 recommendation from NCCN. CAR T-cell therapies are individually made from a patient's own T-cells and infused back into the patient. Yescarta is available at authorized treatment centers across the U.S. and has a safety profile consistent with previous studies. This approval represents a paradigm shift in treating relapsed or refractory LBCL.
On March 8, 2022, Novartis announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies. The agreement allows Novartis to access three capsids from Voyager's platform for potential gene therapies targeting neurological diseases. Novartis aims to address the challenge of biodistribution in deep brain regions. Voyager's capsids from their TRACER platform show improved distribution to neurons in the cortex and deeper brain areas. Novartis plans to evaluate and license these capsids for the development of AAV gene therapies.
28th February 2022 - Santhera Pharmaceuticals partners with SEAL Therapeutics for gene therapy targeting congenital muscular dystrophy (LAMA2 MD). Previous agreements with University Basel and Rutgers end. SEAL Therapeutics aims to develop the therapy and seek a pharmaceutical partner for clinical development. Santhera will receive payments based on future proceeds. This allows Santhera to focus on vamorolone and lonodelestat, their core clinical assets.
Browse 31 Market Data Tables and 23 Figures spread through 178 Pages and in-depth TOC on “Global Regenerative Therapies Market”- Forecast to 2030, Regenerative Therapies Market, by tissue Type (Allograft, Xenograft, Alloplast), By application type (Soft Tissue Repair, Cardiovascular Dental, Orthoped, CNS disease treatment, Others), By End user (Hospitals, Ambulatory Surgical Centers, Educational Institutes) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/regenerative-therapies-market-3712
Key Takeaways of the Global Regenerative Therapies Market Market:
The regenerative therapy market is experiencing significant growth, driven by the increasing prevalence of chronic diseases and advancements in technology. Allografts are the dominant treatment area, while hospitals play a major role in providing comprehensive patient care. North America, particularly the U.S., leads the market. However, challenges such as high costs and regulatory complexities exist. Overall, the market presents opportunities for research, development, and innovative treatment options.
Among Tissue type, In the global regenserative therapy market, allografts are currently the dominant segment, involving the use of tissues or cells from a donor of the same species. Xenografts, which use tissues or cells from a different species, and alloplasts, which are synthetic materials, have a smaller market presence. Ongoing advancements in xenografts and alloplasts could potentially impact the market dynamics in the future.
Among Application type the market is segmented into Soft Tissue Repair, Cardiovascular Dental, Orthoped, CNS disease treatment, Others. Cardiovascular regenerative therapies are a dominant. They aim to repair heart tissue and restore cardiac function using stem cells, tissue engineering, and gene therapies. These therapies hold great promise for treating conditions like heart attacks and heart failure.
Among end user, In the regenerative therapy market, the dominant providers are hospitals, which offer comprehensive patient care. Educational institutes contribute to research and development in the field, while ambulatory surgical centers play a more limited role in providing these therapies.
Among region, the North America is expected to hold a dominant position in the Regenerative Therapies Market Market during the forecast period, owing to increasing the usage of pharmaceuticals and vaccines.
North America held the largest market share in 2021. North America, with its major players and technological advancements in regenerative therapies, is estimated to dominate the market in terms of revenue. The United States, within the region, experiences a high prevalence of diseases such as cancer and diabetes, which can be treated with stem cell therapies.
Major players operating in the global regenerative therapies market include Shire Pharmaceuticals, Kinetic Concepts, Inc., Mesoblast Ltd., Metcela Inc., Nuo Therapeutics (Cytomedix Inc.), Integra LifeSciences, Advanced Cell Technology Inc., BioStem Life Sciences,Akron Biotechnology, LLC, Organovo Holdings Inc., Orgenesis Inc., Pluristem Therapeutics Inc., Genzyme, Athersys, Inc., RenovaCare, Inc., Cytori Therapeutics, Inc.
